Breast Screening in Germany - Few Well-Informed
Breast cancer is the most common type of cancer among women. Early diagnosis through MSP can help to lower the mortality rate. Every two years, women aged between 50 and 69 years are invited to attend the regular screening programme. However, because not every screening delivers a clear outcome, mistakes can sometimes lead to false diagnoses, overtreatment or stress. This has spawned controversy over whether the potential disadvantages of screening possibly outweigh the advantages. For this reason, the concept of informed choice comprising knowledge, attitude and intention has gained importance.
"That is why every woman should take care to find out about the risks and the benefits before accepting the invitation to attend mammography screening," according to Junior Professor Dr. Jacob Spallek, who ran the study together with Professor Petra Kolip.
See also: Breast Cancer Routinely Overdiagnosed in Norway
The goal of the research project was to describe which proportion of women in general and which proportion of women with a Turkish migration background decide in favour of or against MSP — and also make an informed choice. Participants were approximately 5,000 women in the Westphalia-Lippe region who were invited to attend an MSP for the first time.
Overall, 27.1 percent of the invited women made an informed choice for or against participating in the MSP. Whereas 28.2 percent of the women with no migration background made an informed choice, this was 21.8 percent among ethnic German immigrants (Spätaussiedlerinnen) and 20.0 percent among women with other countries of origin. The lowest proportion of informed decisions came from women with a Turkish migration background at 5.0 percent
"The proportion of informed choice is generally low in our study, even among women with high educational level," co-author Eva-Maria Berens told HealthManagement.org. She suggested ways to help more women invited for screening make informed choices. "First of all the official information materials will have to be improved substantially. Currently the information materials in Germany are being revised. But secondly, we need measures to improve women's ability to deal with such complex health information and enable them to critically assess information before making a decision," Berens said.
In Australia and the UK, there has been research and action on information provision on risks and benefits of breast screening so women can have sufficient knowledge about screening and make informed decisions. "There is already some research in that area in Germany," Berens noted. "However, these activities are not tailored for migrants or different education levels. So we will need more research on the special information needs of women with deficiencies in informed choice (namely migrants and women of low education level) and as a second step, interventions to especially target these groups."
Claire Pillar, Managing Editor, HealthManagement.org
Source: Bielefeld University; Interview
Image credit: Bielefeld University
Published on : Fri, 13 Nov 2015
THE VEVO MD IS THE WORLD’S FIRST ULTRA HIGH FREQUENCY ULTRASOUND SYSTEM DESIGNED FOR CLINICAL USE WITH FREQUENCIES UP TO 70 MHz. This groundbreaking technology opens up new possibilities for medical imaging that have never been seen before. Whether...
The enlightened choice for high-field MRI ECHELON Smart is Hitachi’s smart MRI concept which combines ‘SmartQUALITY’ for superb clinical images and sophisticated applications, ‘SmartSPEED’ for reduced examination time, ‘SmartCOMFORT’ for an extraordinary...
Remarkable image quality, right at the point of care. The Trident system revolutionizes breast tissue imaging by incorporating a micro-focused tube, unique specimen image processing algorithms and amorphous selenium direct digital detector. The...
UltraDrape is an innovative dressing designed for use during Ultrasound-Guided Peripheral Intravenous (UGPIV) that provides dual-action barrier and securement in one.
The SonoSite EDGE II is a high-resolution, all-digital, 9.0-pound (4.1 kg) ultrasound system with a 12.1in. LED full-bleed glass display. The Edge II boosts improvements in cardiac and abdominal image quality through DirectClear Technology and a new...